INTRODUCTION
============

Renal cell carcinoma (RCC) accounts for about 85% of kidney cancers ([@B1]), and approximately 25-30% of patients present with advanced RCC, which is defined as metastatic and/or unresectable disease ([@B2]). Metastatic renal-cell carcinoma (mRCC) has always been one of the most drug-resistant malignancies ([@B3]) and the 5-year survival rates remain low at only around 10% and had not improved by 2008 on the basis of the National Cancer Data Base (NCDB) ([@B4]). Over the past two decades, immunomodulating drugs such as interferon-α (IFN) have been the standard first-line mRCC treatment ([@B5]), and have been considered the standard comparator in clinical trials ([@B6]). Recent advances through a better understanding of the molecular mechanisms involved in the pathogenesis of RCC have resulted in the development of drugs that target angiogenesis by either directly inhibiting vascular endothelial growth factor (VEGF)-mediated signalling or indirectly by inhibiting the mammalian target of rapamycin downstream ([@B7]). Compared with previously available treatment options, novel targeted therapies are now providing effective and manageable treatment for patients with advanced RCC with better tolerability ([@B8]). However, these targeted therapies are currently competing to be the primary choice for the first-line therapy of mRCC patients presenting a good or intermediate prognosis. As a consequence of the paucity of head-to-head data with other treatments, it is not possible to directly compare the efficacy of the targeted agents. Hence, in the absence of direct head-to-head comparison, there is a need for appropriate meta-analysis and valid indirect comparison assessment ([@B9]). As the optimal treatment algorithm for the management of advanced RCC remains to be determined, the aim of the current systematic review and meta-analysis was to demonstrate the clinical efficacy of different targeted treatments for the management of patients with advanced RCC and use indirect comparisons to provide an optimal option among these agents.

MATERIALS AND METHODS
=====================

Literature search and study selection
-------------------------------------

A systematic search of the electronic databases, including Medline, Scopus and Cochrane Library was performed to identify trials on the targeted therapies of advanced RCC up to January 1, 2015 which was when the search was completed. The strategy consisted of searching for publications using key terms related to the target drugs (e.g., agents' names) and various terms used to describe renal cancer included renal cancer or renal tumor or renal neoplasm or renal carcinoma. We also sought unpublished studies through "[clinicaltrials.gov](http://clinicaltrials.gov)". No temporal, regional, publication status or language restrictions were set. In addition, a full manual search of the references in each relevant article was also conducted.

Inclusion criteria and exclusion criteria
-----------------------------------------

We included any randomized clinical trial evaluating the therapeutic efficacy of VEGF(r)-TKI bevacizumab, sorafenib, sunitinib, pazopanib, tivozanib, or cediranib and the mTOR inhibitor temsirolimus, everolimus for the treatment of mRCC. Studies had to evaluate one of the study drugs combination or monotherapy with a control intervention. We included trials involving patients of any age, sex, or mRCC stage. We excluded pharmacokinetic studies, nonrandomized evaluations, animal studies and laboratory studies.

Data extraction and outcomes of interest
----------------------------------------

Two reviewers (H.B.X. and P.J.L.) extracted independently the following data including: first author, year of publication, trial name, trial phase, published journal, prior therapy, the intervention and comparator agents, number of patients and outcomes of interest. All disagreements about eligibility were resolved by a third reviewer (H.X.) by discussion until a consensus was reached. Our primary outcome was PFS, the most consistently reported endpoint. Key secondary effectiveness outcomes included OS, ORR by RECIST (Response Evaluation Criteria in Solid Tumors) criteria, and patient-reported outcomes.

Study quality and level of evidence
-----------------------------------

The quality appraisal of included studies was analyzed using the Jadad scale ([@B10]). Two reviewers (H.B.X. and ZhL.X.) independently assessed the quality of the studies and disagreement was resolved by consensus.

HR pooled
---------

Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the impact of targeted therapies on PFS and OS. A combined HR \>1 implied a worse survival, and it was considered statistically significant if 95% CI for the combined HR did not overlap 1. For the studies in which HR was not given directly, the published data and figures from original papers were used to calculate the HR according to the methods described by Parmar et al ([@B11]). The O-E and variance were calculated from the reported data directly by HR and its 95% CI or indirectly by log-rank *P* value with number of events, or data reading from Kaplan-Meier survival curve. All *P* values are two-tailed with a significant level at 0.05. Kaplan-Meier curves were read by Engauge Digitizer version 4.1 (<http://digitizer.sourceforge.net/>) (12). This work was performed by two independent persons to reduce inaccuracy in the extracted survival rates. Discrepancies in these articles were resolved by discussion.

Indirect treatment comparison
-----------------------------

Standard indirect comparison methods were applied to independent review PFS data of the randomized trials, to indirect treatment comparison (ITC) HR with 95% CI. If there are two agents and both have been compared to another, indirect comparison was enabled by the common comparator arms. The ITC of PFS outcomes uses the most widely applied indirect comparison method by Bucher et al. ([@B13]). The PFS HRs of eligible RCTs were selected as the preferred outcome for the ITC, as this effect measure accounts for censoring and incorporates time to event information ([Table-1](#t1){ref-type="table"}) ([@B14]). Each trial PFS outcomes which present the highest quality data based on independent central review assessment were also selected as the basis of the ITC ([Table-2](#t2){ref-type="table"}). For example, trial TARGET and NCT00079612 reported the comparison between Sorafenib and placebo, while trial RECORD-1 reported Everolimus vs placebo, as Everolimus and Sorafenib have been compared to placebo, ITC was enabled by the common placebo control arms. As shown in Supplementary protocol designs ([Appendix](#APP1){ref-type="app"}), for the trails such as TARGET and RECORD-1 in which patient characteristics, enrolment criterion, and study measurements are comparable, but not identical, ITC was conducted and the other ITCs were also carried according to this protocol. All calculations have been performed by our advanced setting program in Excel 2007 (Microsoft Office). The ITC calculations can also be reperformed using the ITC tool available from Wells et al. which ensures maximum transparency ([@B15]). We did not perform an indirect comparison of the effect of interventions on OS data because there was a lack of final OS data reported in the studies analyzed and because of uncertainty regarding post study medication usage.

###### Pooled outcomes of included randomized trials.

  Trail                                                         PFS, months (Int vs. Con)           HR (95% CI)        P          ORR %          P                                   OS, months (Int vs. Con)                            HR (95% CI)        P
  ------------------------------------------------------------- ----------------------------------- ------------------ ---------- -------------- ----------------------------------- --------------------------------------------------- ------------------ -------
  **VEGF(r)-TKI & mTOR inhibitor vs placebo**                                                                                                                                                                                                               
  NCT00019539 ([@B16])                                          4.8/2.5                             0.43 (0.26-0.72)   \<0.0001   10 vs 0        ns                                  nr                                                  0.84(0.58-1.22)    ns
  NCT00079612 ([@B17])                                          5.5/1.4                             0.42 (0.20-0.91)   0.009      nr             nr                                  nr                                                  nr                 nr
  TARGET ([@B18], [@B19])                                       5.5/2.8                             0.51 (0.43-0.60)   \<0.0001   2 vs 0         ns                                  17.8/15.2                                           0.88(0.74-1.04)    0.146
  VEG 105192 ([@B20]-[@B22])                                    9.2 (7.4-12.9)/4.2 (2.8-4.2)        0.46 (0.34-0.62)   \<0.0001   30 vs 3        \<0.0001                            22.9 (19.9-25.4)/20.5 (15.6-27.6)                   0.91 (0.71-1.16)   0.224
  NCT00502307 ([@B23])                                          10.3 (8.1-21.2)/3.3 (1.8-8.0)       0.55 (0.33-0.91)   0.01       nr             nr,                                 nr                                                  nr                 nr
  NCT00423332 ([@B24])                                          12.1/2.76                           0.45 (0.26-0.78)   0.017      34 vs 5.56     nr                                  nr                                                  nr                 nr
  RECORD-1 ([@B25])                                             4.0 (3.7-5.5)/1.9 (1.8-1.9)         0.30 (0.22-0.40)   \<0.0001   1 vs 0         ns                                  NA/8.8 (7.9-NA)                                     0.83(0.50-1.37)    0.23
  **VEGF(r)-TKI & mTOR inhibitor vs IFN-**α                                                                                                                                                                                                                 
  CALGB 90206 ([@B26])                                          8.5 (7.5-9.7)/5.2 (3.1-5.6)         0.71 (0.61-0.83)   \<0.0001   25.5 vs 13.1   \<0.0001                            nr                                                  nr                 nr
  AVOREN ([@B27]-[@B28])                                        5.5/2.8                             0.51 (0.43-0.60)   \<0.0001   31 vs 13       \<0.0001                            17.8/15.2                                           0.88(0.74-1.04)    0.146
  NCT00117637 ([@B29])                                          5.7 (5.0-7.4)/5.6 (3.7-7.4)         0.88 (0.61-1.27)   0.504      5.2 vs 8.6     ns                                  nr                                                  nr                 nr
  NCT00083889 ([@B30])                                          11 (10-12)/5 (4-6)                  0.42 (0.32-0.54)   \<0.0001   11 vs 5        0.54                                114.6 (100.1-142.9)/94.9 (77.7-117)                 0.65(0.45-0.94)    0.02
  Global ARCC ([@B31])                                          3.8 (3.6-5.2)/1.9 (1.9-2.2)         0.76 (0.62-0.92)   \<0.0001   8.6 vs 4.8     ns                                  10.9 (8.6-12.7)/7.3 (6.1-8.8)                       0.73(0.58-0.92)    0.008
  **VEGF(r)-TKI & mTOR inhibitor combination vs monotherapy**                                                                                                                                                                                               
  NCT00126594 ([@B32])                                          7.56 (5.19-11.07)/7.39 (5.5-9.2)    0.85 (0.51-1.42)   0.53       30 vs 25       ns                                  27.04 (22.31- NA)/NA                                1.95(0.84-4.52)    0.122
  ROSORC ([@B33])                                               33/20                               0.75 (0.34-1.65)   0.11       27.3 vs 14.5   ns                                  nr                                                  nr                 nr
  NCT00467025 ([@B34])                                          9.0 (5.6-13.1)/9.0 (5.5-10.9)       0.8 (0.5-1.28)     0.35       38 vs 25       ns                                  nr                                                  nr                 nr
  Global ARCC ([@B31])                                          3.7 (2.9-4.4)/3.8 (3.6-5.2)         1.08 (0.89-1.3)    ns         8.1 vs 8.6     ns                                  8.4 (6.6-10.3)/10.9 (8.6-12.7)                      1.19(0.94-1.50)    ns
  **Single VEGF(r)-TKI & mTOR inhibitor comparison**                                                                                                                                                                                                        
  AXIS ([@B35])                                                 12.1 (8.6-NA)/4.9 (2.8-6.6)         0.39 (0.13-1.17)   0.04       52 vs 3.4      0.0001                              nr                                                  nr                 nr
  AXIS ([@B36], [@B37])                                         8.3 (6.7-9.2)/5.7 (4.7-6.5)         0.66 (0.55-0.78)   \<0.0001   19.4 vs 9.4    0.0001                              20.1 (16.7-23.4)/19.2 (17.5-22.3)                   0.97(0.80-1.17)    0.37
  INTORSECT ([@B38])                                            4.28 (4.01-5.43)/3.91 (2.80-4.21)   0.87 (0.71-1.07)   0.19       7.7 vs 7.9     ns                                  (17.5-22.3) 12.27 (10.13-14.8)/16.64(13.55-18.72)   1.31(1.05-1.63)    0.014
  COMPARZ ([@B39])                                              8.4 (8.3-10.9)/9.5 (8.3-11.1)       1.05 (0.90-1.22)   ns         30.7 vs 24.8   28.4 (26.2-35.6)/29.3 (25.3-32.5)   nr                                                  nr                 
  NCT01147822 ([@B40])                                          8.4 (8.3-11.1)/11.1 (8.2-14.3)      1.02 (0.77-1.35)   ns         35.6 vs 20.7   NA (23.7-NA)/31.5(29.5-NA)          nr                                                  nr                 
  **VEGF(r)-TKI & mTOR inhibitor combined treatment**                                                                                                                                                                                                       
  AVOREN ([@B27])                                               23.3/26                             0.92 (0.69-1.23)   ns         nr             nr                                  nr                                                  nr                 nr
  RAPSODY ([@B42])                                              7.9 (5.1-10.9)/8.6 (2.2-15.1)       1.35 (1.01-1.59)   0.049      17.6 vs 34     0.058                               20.3 (20.5-32.4)/19.4 (23.4-36.8)                   1.17(0.69-2.00)    0.412
  Bukowski, 2007 ([@B43])                                       9.9/8.5                             0.86 (0.50-1.49)   0.58       14 vs 13       0.99                                20/NA                                               1.57(0.84-2.94)    0.16
  INTORACT ([@B44])                                             9.1 (8.1-10.2)/9.3 (9.0-11.2)       1.1 (0.9-1.3)      ns         27 vs 27.4     1.0                                 25.8 (21.1-30.7)/25.5 (20.4-30.8)                   1.0(0.9-1.3)       0.6
  TORAVA ([@B45])                                               8.2 (7.0-9.6)/16.8 (6.0-26.0)       1.21 (0.7-2.09)    ns         27 vs 43       nr                                  nr                                                  nr                 nr
  TORAVA ([@B45])                                               8.2 (5.5-11.7)/16.8 (6.0-26.0)      1.62 (0.84-3.16)   ns         29 vs 43       nr                                  nr                                                  nr                 nr

**VEGF(r)-TKI =** vascular epithelial growth factor (receptor) tyrosine kinase inhibitor; **mTOR =** mammalian target of rapamycin; **PFS =** progression free survival; **OS =** overall survival; **ORR =** objective response rate; **HR =** hazard ratio; 95% CI, 95% confidence interval; **ns =** not statistically significant; **nr =** not reported; **NA =** not attained. Data of HR estimated through Kaplan-Meier curves is indicated in italic, and remaining data is as reported by investigators.

###### Summary of included randomized studies.

  Reference                                                     Trial name    Phase       Journal            Prior therapy   Intervention          Comparator          Patients   Outcomes
  ------------------------------------------------------------- ------------- ----------- ------------------ --------------- --------------------- ------------------- ---------- --------------
  **VEGF(r)-TKI & mTOR inhibitor vs placebo**                                                                                                                                     
  Yang, 2003 ([@B16])                                           NCT00019539   Phase II    N Engl J Med       IL2             BEV 10 mg             Placebo             39/40      OS, PFS, ORR
  Ratain, 2006 ([@B17])                                         NCT00079612   Phase II    J Clin Oncol       cytokine        Sorafenib             Placebo             32/33      PFS, ORR
  Escudier, 2007 ([@B18])                                       TARGET        Phase III   N Engl J Med       cytokine        Sorafenib             Placebo             451/452    OS, PFS, ORR
  Escudier, 2009 ([@B19])                                       TARGET        Phase III   J Clin Oncol       cytokine        Sorafenib             Placebo             451/452    OS, PFS, ORR
  Nieto, 2011 ([@B20])                                          VEG 105192    Phase III   Clin Cancer Res    Nil, ifn α      Pazopanib             Placebo             155/78     OS, PFS, ORR
  Sternberg, 2010 ([@B21])                                      VEG 105192    Phase III   J Clin Oncol       Nil, ifn α      Pazopanib             Placebo             290/145    PFS, ORR
  Sternberg, 2013 ([@B22])                                      VEG 105192    Phase III   Eur J Cancer       Nil, ifn α      Pazopanib             Placebo             290/145    OS, ORR
  Nosov, 2012 ([@B23])                                          NCT00502307   Phase II    J Clin Oncol       Nil, ifn α      Tivozanib 3/1         Placebo             51/51      PFS, ORR
  Mulders, 2012 ([@B24])                                        NCT00423332   Phase II    Eur J Cancer       Nil             Cediranib             Placebo             53/18      PFS, ORR
  Motzer, 2008 ([@B25])                                         RECORD-1      Phase III   Lancet             VEGFr-TKI       Everolimus            Placebo             272/138    OS, PFS, ORR
  **VEGF(r)-TKI & mTOR inhibitor vs IFN**-**α**                                                                                                                                   
  Rini, 2008 ([@B26])                                           CALGB 90206   Phase III   J Clin Oncol       Nil             BEV + IFN α           IFN α               369/363    PFS, ORR
  Melichar, 2012 ([@B27])                                       AVOREN        Phase III   ERA Ther           Nil             BEV + IFN α           IFN α               327/322    OS, PFS, ORR
  Escudier, 2007 ([@B28])                                       AVOREN        Phase III   Lancet             Nil             BEV + IFN α           IFN α               327/322    OS, PFS, ORR
  Escudier, 2010 ([@B29])                                       AVOREN        Phase III   J Clin Oncol       Nil             BEV + IFN α           IFN α               327/322    OS, ORR
  Escudier, 2009 ([@B30])                                       NCT00117637   Phase II    J Clin Oncol       Nil             Sorafenib             IFN α               97/92      PFS
  Motzer, 2007 ([@B31])                                         NCT00083889   Phase III   N Engl J Med       Nil             Sunitinib 4/2         IFN α               375/375    OS, PFS, ORR
  Hudes, 2007 ([@B32])                                          Global ARCC   Phase III   N Engl J Med       Nil             Temsirolimus          IFN α               209/207    OS, PFS, ORR
  **VEGF(r)-TKI & mTOR inhibitor combination vs monotherapy**                                                                                                                     
  Jonasch, 2010 ([@B33])                                        NCT00126594   Phase II    Cancer             Nil             Sorafenib + IFN α     Sorafenib           40/40      OS, PFS, ORR
  Procopio, 2011 ([@B34])                                       ROSORC        Phase II    Brit J Cancer      Nil             Sorafenib + IL2       Sorafenib           66/62      PFS, ORR
  Rini, 2012 ([@B35])                                           NCT00467025   Phase II    Cancer             Nil             Sorafenib + AMG386    Sorafenib           50/51      PFS, ORR
  Hudes, 2007 ([@B32])                                          Global ARCC   Phase III   N Engl J Med       Nil             Temsirolimus + IFN    Temsirolimus        210/209    OS, PFS, ORR
  **Single VEGF(r)-TKI & mTOR inhibitor comparison**                                                                                                                              
  Ueda, 2013 ([@B36])                                           AXIS          Phase III   Jpn J Clin Oncol   Any one         Axitinib              Sorafenib           25/29      PFS, ORR
  Motzer, 2013 ([@B37])                                         NCT00678392   Phase III   Lancet Oncol       Any one         Axitinib              Sorafenib           361/362    PFS, OS, ORR
  Rini, 2011 ([@B38])                                           AXIS          Phase III   Lancet             Any one         Axitinib              Sorafenib           361/362    PFS, ORR
  NCT00474786 ([@B39])                                          INTORSECT     Phase III   unpublished        Sunitinib       Temsirolimus          Sorafenib           259/253    OS, PFS, ORR
  Celler, 2013 ([@B40])                                         COMPARZ       Phase III   J Clin Oncol       Nil             Pazopanib             Sorafenib           557/553    OS, PFS, ORR
  NCT01147822 ([@B41])                                          NCT01147822   Phase II    unpublished        Nil             Pazopanib             Sunitinib           188/179    OS, PFS, ORR
  **VEGF(r)-TKI & mTOR inhibitor combined treatment**                                                                                                                             
  Escudier, 2010 ([@B29])                                       AVOREN        Phase III   J Clin Oncol       Nil             BEV + LD-IFN α        BEV + IFN α         13/3271    OS, ORR
  Bracarda, 2007 ([@B42])                                       RAPSODY       Phase II    Eur Urol           Nil             Sorafenib + IFN α×5   Sorafenib + IFN α   51/50      OS, PFS, ORR
  Bukowski, 2007 ([@B43])                                       NCT00081614   Phase II    J Clin Oncol       Nil             BEV + Erlotinib       BEV + Placebo       53/51      PFS, OS, ORR
  NCT00631371 ([@B44])                                          INTORACT      Phase III   unpublished        Nil             BEV + Everolimus      BEV + IFN α         400/391    PFS, OS, ORR
  Négrier, 2011 ([@B45])                                        TORAVA        Phase II    Lancet Oncol       Nil             BEV + Temsirolimus    BEV + IFN α         88/41      PFS, ORR
  Négrier, 2011 ([@B45])                                        TORAVA        Phase II    Lancet Oncol       Nil             Sunitinib             BEV + IFN α         42/41      PFS, ORR

**VEGF(r)-TKI =** vascular epithelial growth factor (receptor) tyrosine kinase inhibitor; **mTOR =** mammalian target of rapamycin; **PFS =** progression free survival; **OS =** overall survival; **ORR =** objective response rate; **IFN-α** = interferon-α; **BEV =** bevacizumab. Primary outcome in each study is indicated in bold.

### Statistical analysis

We performed the meta-analysis by using the Review Manager Software (RevMan 5.1, Cochrane Collaboration, Oxford, UK). χ^2^ and I^2^ statistics were used directly to examine the heterogeneity between each study. By heterogeneity test, if I^2^\<50%, we select the fixed-effect model, and if not, a random-effect model was used. We used HR, risk ratio (RR) and their CIs to evaluate the relationship between the targeted therapies and survival and ORR in advanced RCC, respectively. To test the publication bias, we used the RevMan 5.1 statistical software to make the funnel plot. P\<0.05 was considered as significant difference.

RESULTS
=======

Characteristics of included studies and study quality
-----------------------------------------------------

Thirty eligible randomized controlled studies, total twenty-four trails (5110 cases and 4626 controls) were identified ([Figure-1](#f1){ref-type="fig"}). 19 studies were Phase III, international, multicenter, randomized clinical trials; and 11 studies were Phase II trials. There were 10 placebo control RCTs and 7 control RCTs. 4 studies compared combination vs monotherapy, 6 studies conducted comparison between single VEGF(r)-TKI & mTOR inhibitor and 5 studies performed comparison between combined treatments. First author, year of publication, trial name, trial phase, published journal, prior therapy, the intervention and comparator agents, number of patients and outcomes of interest were extracted individually from each study and listed on [Table-2](#t2){ref-type="table"}. We utilized the Jadad scale to assess the quality of every study included in our meta-analysis. Above the 30 RCTs ([@B16]-[@B45]) twenty-four studies ([@B16]-[@B23], [@B25], [@B26], [@B28], [@B45]) scored a 5 because the description of randomization and technique was adequate. By contrast, the other six studies ([@B24], [@B27], [@B30], [@B33], [@B35], [@B36]) scored a 3 on the Jadad scale because the description of double-blind or the method of blinding was inappropriate ([Supplementary Table-1](#t3){ref-type="table"}). In addition, according to Jadad scale and Oxford Centre for Evidence\--based Medicine Levels of Evidence, we judged the strength of evidence of every study included in our meta-analysis to be Ib. Also, the effectiveness outcomes including PFS, OS, ORR and pooled HR were extracted in [Table-2](#t2){ref-type="table"}.

![Flow diagram showing the selection process of included studies.](1677-5538-ibju-44-02-0219-gf01){#f1}

###### Quality assessments for each study with Jadad scale.

  Questions                   Randomized Study?   Randomization technique described and adequate   Randomization technique described and inadequate   Double blinded study?   Technique of blinding described and adequate   Technique of blinding described and inadequate   Description of withdrawals and dropouts?   Jaded score
  --------------------------- ------------------- ------------------------------------------------ -------------------------------------------------- ----------------------- ---------------------------------------------- ------------------------------------------------ ------------------------------------------ -------------
  Yang, 2003 \[[@B1]\]        Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Ratain, 2006 \[[@B2]\]      Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Escudier, 2007 \[[@B3]\]    Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Escudier, 2009 \[[@B4]\]    Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Nieto, 2011 \[[@B5]\]       Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Sternberg, 2010 \[[@B6]\]   Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Sternberg, 2013 \[[@B7]\]   Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Nosov, 2012 \[[@B8]\]       Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Mulders, 2012 \[[@B9]\]     Yes                 Yes                                              No                                                 No                      No                                             No                                               Yes                                        3
  Motzer, 2008 \[[@B10]\]     Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Rini, 2008 \[[@B11]\]       Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Melichar, 2012 \[[@B12]\]   Yes                 Yes                                              No                                                 No                      No                                             No                                               Yes                                        3
  Escudier, 2007 \[[@B13]\]   Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Escudier, 2010 \[[@B14]\]   Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Escudier, 2009 \[[@B15]\]   Yes                 Yes                                              No                                                 No                      No                                             No                                               Yes                                        3
  Motzer, 2007 \[[@B16]\]     Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Hudes, 2007 \[[@B17]\]      Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Jonasch, 2010 \[[@B18]\]    Yes                 Yes                                              No                                                 No                      No                                             No                                               Yes                                        3
  Procopio, 2011 \[[@B19]\]   Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Rini, 2012 \[[@B20]\]       Yes                 Yes                                              No                                                 No                      No                                             No                                               Yes                                        3
  Ueda, 2013 \[[@B21]\]       Yes                 Yes                                              No                                                 No                      No                                             No                                               Yes                                        3
  Motzer, 2013 \[[@B22]\]     Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Rini, 2011 \[[@B23]\]       Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  NCT00474786 \[[@B24]\]      Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Celler, 2013 \[[@B25]\]     Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  NCT01147822 \[[@B26]\]      Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Bracarda, 2007 \[[@B27]\]   Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Bukowski, 2007\[[@B28]\]    Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  NCT00631371 \[[@B29]\]      Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5
  Négrier, 2011 \[[@B30]\]    Yes                 Yes                                              No                                                 Yes                     Yes                                            No                                               Yes                                        5

VEGF(r)-TKI & mTOR inhibitor vs placebo
---------------------------------------

Compared with placebo, VEGF(r)-TKI & mTOR inhibitor were associated with improved PFS (HR: 0.45; 95% CI: 0.40-0.51; P\<0.001; [Figure-2](#f2){ref-type="fig"}), improved OS (HR: 0.88; 95% CI, 0.78-1.00; P=0.05; [Figure-3](#f3){ref-type="fig"}) and higher ORR (RR: 2.21; 95% CI, 1.53-3.91; P\<0.001; [Figure-4](#f4){ref-type="fig"}), respectively.

![Forest plot and meta-analysis of PFS comparing VEGF(r)-TKI & mTOR inhibitor vs placebo.](1677-5538-ibju-44-02-0219-gf02){#f2}

![Forest plot and meta-analysis of OS comparing VEGF(r)-TKI & mTOR inhibitor vs placebo.](1677-5538-ibju-44-02-0219-gf03){#f3}

![Forest plot and meta-analysis of ORR comparing VEGF(r)-TKI & mTOR inhibitor vs placebo.](1677-5538-ibju-44-02-0219-gf04){#f4}

VEGF(r)-TKI & mTOR inhibitor vs IFN-α
-------------------------------------

Compared with IFN-α, VEGF(r)-TKI & mTOR inhibitor were associated with improved PFS (HR: 0.62; 95% CI, 0.57-0.68; P\<0.001; [Figure-5](#f5){ref-type="fig"}), improved OS (HR: 0.80; 95% CI, 0.70-0.91; P\<0.001; [Figure-6](#f6){ref-type="fig"}) and higher ORR (RR: 2.30; 95% CI, 1.83-2.90; P\<0.001; [Figure-7](#f7){ref-type="fig"}), respectively.

![Forest plot and meta-analysis of PFS comparing VEGF(r)-TKI & mTOR inhibitor vs IFN-α.](1677-5538-ibju-44-02-0219-gf05){#f5}

![Forest plot and meta-analysis of OS comparing VEGF(r)-TKI & mTOR inhibitor vs IFN-α.](1677-5538-ibju-44-02-0219-gf06){#f6}

![Forest plot and meta-analysis of ORR comparing VEGF(r)-TKI & mTOR inhibitor vs IFN-α.](1677-5538-ibju-44-02-0219-gf07){#f7}

Efficacy of sorafenib and BEV + IFN-α
-------------------------------------

Three trials ([@B33]-[@B35]) compared sorafenib combination vs sorafenib; there was no significant difference with regard to PFS (HR: 0.81; 95% CI, 0.59-1.11; P=0.19) and OS (HR: 1.95; 95% CI, 0.84-4.52; P=0.12), but with a higher ORR (RR: 1.51; 95% CI, 1.03-2.22; P=0.03). Three trials ([@B29], [@B44], [@B45]) compared single or combination VEGF(r)\--TKI & mTOR inhibitor vs BEV + IFN-α; there was no significant difference with regard to PFS (HR: 1.08; 95% CI, 0.93-1.25; P=0.31), OS (HR: 1.0; 95% CI, 0.9-1.3; P=0.6), or ORR (RR: 0.85; 95% CI, 0.65-1.12; P=0.26).

Indirect treatment comparison and the network diagram of HR for PFS
-------------------------------------------------------------------

Pooled HRs by the indirect treatment comparison (ITC) of PFS are listed in [Figure-8](#f8){ref-type="fig"}. By the ITC, axitinib was superior to sorafenib (HR: 0.65; 95% CI, 0.55-0.77) and temsirolimus (HR: 0.75; 95% CI, 0.57-0.97). Everolimus improved PFS versus sorafenib (HR: 0.59; 95% CI, 0.42-0.82). There were no significant differences between the second line targeted therapies as shown in [Figure-8](#f8){ref-type="fig"}. In order of superiority of HR for PFS we made a network diagram of a ranking of the current treatments ([Figure-9](#f9){ref-type="fig"}). Three level ranking system were introduced, that is, IFN-α as the front line cytokine therapy, everolimus and axitinib as the second line agents after failure of initial VEGF(r)-TKI & mTOR inhibitor treatment, and the others remaining as the first line targeted therapies.
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DISCUSSION
==========

Interferon alpha (IFN-α) as the standard of care for mRCC prior to 2005 demonstrated to be associated with limited efficacy and high toxicity in our meta-analysis and only remains an option for front-line cytokine therapy in a small minority of highly selected patients with a good prognosis, which was consistent with the previous studies ([@B47], [@B48]). Treatment for advanced RCC has dramatically changed since 2006 with several targeted agents currently approved for the treatment of advanced RCC, including sunitinib, sorafenib, temsirolimus, everolimus, bevacizumab (in combination with IFN) and pazopanib. With new agents in development, the treatment options for advanced RCC are set to increase further. While head-to-head trials remain the gold standard, as trials need several years to complete, the dynamic advanced RCC treatment environment means that the comparator while appropriate at the time of trial design may not be optimal. In the absence of head-to-head data available at the time of this research, indirect comparisons via systematic review and network meta-analysis provide a robust clinical reference in the evolving treatment of advanced RCC.

Improved efficacy of VEGF(r)-TKI & mTOR inhibitor vs placebo and IFN-α
----------------------------------------------------------------------

Improvements in PFS, OS and ORR benefits vs IFN-α or placebo comparators were demonstrated for all of the available targeted therapies, although some class distinctions were evident between the VEGF(r)-TKI and the mTOR inhibitors. Consistent with their mechanism of action, temsirolimus and everolimus, when used as monotherapy, are primarily cytostatic and appear to affect PFS by stabilizing the disease. Thus, for mTOR inhibitors, although ORR achieved in some patients, might not be clinical benefit in RCC. In the RECORD-1 placebo controlled study, everolimus gained an ORR of 1%, and Global ARCC trial indicated 8.6% versus IFN-α. By contrast, the higher ORRs with sunitinib (11%), sorfenib (2-5.2%), pazopanib (30%), cediranib (34%) or bevacizumab + IFN-α (25.5-31%) obtained in previously untreated patients suggest that tumor regression might play a larger role in the improvement in PFS shown with angiogenesis inhibitors. Eisen et al. also conducted a subgroup analysis of the pivotal TARGET trial which demonstrated that sorafenib conferred a statistically significant increase in PFS and increased clinical benefit. The maintained efficacy combined with an acceptable toxicity profile in both younger and older patients, supports the use of sorafenib as a treatment for advanced RCC in all age groups ([@B49]). TIVO-1 ([@B23]) trial suggested tivozanib as an orally bioavailable VEGF(r)-TKI had a long half-life and excellent potency and specificity to the VEGF receptors. The drug has shown tolerability and efficacy in early phase trials and has shown superiority to sorafenib in terms of improved PFS and acceptable toxicity profile in patients with metastatic RCC. FDA has not approved tivozanib ([@B50]), the activity and safety of tivozanib still required the observation in the ongoing phase III evaluation of tivozanib in patients with advanced or metastatic clear-cell RCC.

First line targeted therapies of mRCC
-------------------------------------

Bevacizumab, which has proven to be well tolerated and efficacious in mRCC when combined with cytotoxic chemotherapy, has demonstrated significant clinical benefits in patients with mRCC when combined with IFN-α ([@B51]). In the past, there was a consensus that single VEGF(r)-TKI & mTOR inhibitor agents and BEV+IFN are equally effective in terms of PFS in first-line mRCC therapy ([@B52]); however, recent publications ([@B53], [@B54]) raised doubts about this comparable efficacy. Our study with expanded-access-study applied indicated a comparable result which is in line with Mickisch et al. findings. Still, number of studies ([@B43]-[@B45]) explored the combination of bevacizumab with other targeted agents which may display improved efficacy through blockade of the angiogenic pathways at multiple points. However, a recent study in patients with metastatic RCC also showed that the combination of sunitinib plus bevacizumab is not feasible because of a high side reaction of hypertension and vascular and hematological toxicities with chronic therapy ([@B48]). Notably, combining bevacizumab with mTOR inhibitors such as everolimus ([@B44]) and temsirolimus ([@B45]) also out of interest and appears not promising based on preliminary data with attenuated efficacy (HR, 1.1; PFS, 9.1 vs 9.3 mon; ORR, 27 vs 27.4%) and (HR, 1.21; PFS, 8.2 vs 16.8 mon; ORR, 27 vs 43%). And the toxicity profile of the combination of mTOR inhibitors and bevacizumab at full doses of each drug was much higher than anticipated and limited treatment continuation over time. This combination has failed to show any beneficial activity when used as first-li-ne treatment in patients with mRCC and cannot be suitable for recommendation. In conclusion, it is conceivable that bevacizumab monotherapy could provide a safety advantage over its combination with IFN-a, VEGF(r)-TKI and mTOR inhibitor combined chemotherapy.

Sorafenib has been the best-evidenced second-line option after cytokine failure, until the AXIS study discussed below. Subsequent emphasis has been on attempted enhancement of activity by combining sorafenib with other agents, including low dose IFN-α ([@B33]), IL-2 ([@B34]), and AMG 386 ([@B35]). However, no clinically useful advance comparing these combinations with sorafenib alone has been identified. Our network analysis also provides a ranking of the single VEGF(r)-TKI agent treatments in order of superiority. In all trials, axitinib was ranked most likely to be 'best', followed by cediranib, sorafenib, sunitinib, pazopanib and tivozanib. Different with the results by James et al. which showed sorafenib followed by pazopanib in superiority according to an indirect comparison with two placebo control trials, we draw the conclusion from the COMPARZ head-to-head studies ([@B30]). Also Mills et al. ([@B53]) conducted an indirect comparison with IFN-α as the common comparator, finding that sunitinib has a superior potency compared with sorafenib (HR: 0.58, 95% CI, 0.38-0.86) and is associated with a high rate of CR ([@B55], [@B56]). However, in our meta-analysis assessing the efficacy of VEGF(r)-TKI & mTOR inhibitor vs IFN-α, except for the study ([@B30]) comparing sorafenib vs IFN-α (HR: 0.88, 95% CI, 0.61-1.27) all remaining studies showed a significant difference, and the one study removed test showed a significant heterogeneity. Considering the inherent limitations, the two IFN-α controlled trials were not suitable for ITC, and finally we performed ITC with two pazopanib controlled trials ([@B25], [@B26]) which may be much credible. Based on the current clinical evidence, BEV+ IFN-α, sorafenib and sunitinib considered as the first-line treatments for metastatic RCC are widely used in patients who have failed prior front cytokine therapy, except in patients with poor-risk features, for whom temsirolimus is the recommended first-line treatment.

Also, two recent trials ([@B29], [@B42]) trying to compare lower versus standard IFN-α combined with bevacizumab and sorafenib, both of which demonstrated that plus frequent low-dose IFN-α enhanced efficacy and tolerability in comparison with standard-dose IFN-α. Alternatively, frequent lower IFN-α may still play a role and warranted to be identified in combination with other available VEGF(r)-TKI agents for the treatment of mRCC.

Second line targeted therapies of mRCC
--------------------------------------

Considering the studies identified in the current meta-analysis, both the AXIS ([@B36]-[@B38]) and RECORD-1 ([@B25]) studies enrolled patients or a subgroup of patients who were pretreated with TKIs. However, there were several issues which precluded an appropriate comparison of the relative efficacy of axitinib and everolimus in the TKI-refractory population. For example, patients enrolled in the AXIS study ([@B37]) were strictly second line (cytokine & sunitinib-refractory) compared with those enrolled in the RECORD-1 study ([@B38]) where all patients had received a minimum of one line of treatment (prior treated with sunitinib & sorafenib) and 79% had received two or more prior treatments. As it would be expected, the analysis findings are consistent with those from the AXIS head-to-head clinical trial ([@B36]-[@B38]) which indicate that treatment with axitinib has a statistically and clinically significant advantage over treatment with single VEGF(r)-TKI agent alone in terms of PFS in patients with previously treated mRCC in the overall population. Moreover, time to deterioration also favored axitinib, supporting the idea that prolonging disease control connotes clinical benefit in this treatment setting. The tolerability of axitinib generally was similar to sorafenib and other similar VEGF(r)-TKIs. In addition, results by Ueda et al. demonstrated the PFS advantage of axitinib over sorafenib was maintained in Japanese subgroup ([@B36]) when time to symptom deterioration was included with the overall efficacy assessment, consistent with the overall population ([@B37], [@B38]) and indicated that axitinib provides extended symptom and disease control for these patients. Furthermore, median PFS and ORR achieved in axitinib treated Japanese patients were longer and higher than those achieved in the overall population treated with axitinib.

Everolimus is the first oral mTOR inhibitor to be evaluated in RCC, and has a different active form from temsirolimus. RECORD-1 ([@B25]) compared everolimus with placebo with progressive disease of initial sunitinib and/or sorafenib treatment. The primary endpoint of PFS by independent central review was improved (median PFS 4.9 vs 1.9 months, HR: 0.33, P\<0.001). OS was the same in both arms, although everolimus was used in 76% of placebo-assigned patients after disease progression. Our network ITC meta-analysis also indicated a superior PFS (HR: 0.59; 0.42-0.82) compared to sorafenib. Findings here are consistent with a recently published systematic review, which included an adjusted comparison of the effects of treatment with axitinib that was superior compared with sorafenib and pazopanib on PFS for mRCC in terms of PFS ([@B57]).

Results from our present study indicated that axitinib and everolimus will be important treatment options to extend PFS that should be considered as effective second-line treatment option in the management of advanced RCC. It is not apparent from comparison of PFS of axitinib in this trial and of everolimus in the RECORD-1 trial that switching mechanism of action or maintaining VEGF suppression is a superior strategy in patients with renal cell carcinoma. Further information to determine the optimal treatment algorithm in the second-line management of advanced RCC with regard to the sequence of treatments may come from ongoing trials ([@B58]). However, it is important that further robust head-to-head RCTs must be carried out in order to assess the relative efficacies of treatments in a clinically relevant population, that is, after failure of initial VEGF-targeted therapy. In conclusion, the present systematic review/meta-analysis indicated that recently raising targeted agents, axitinib and everolimus as the second-line setting, may offer improvements in terms of PFS compared with the more established agents.

Evidence strengths and limitations
----------------------------------

However, we should admit that there existed certain inherent limitations in the trials included in our meta-analysis that cannot be ignored when interpreting our data. The major limitation is that our findings are partially based on indirect evidence. Although ITC allows indirect estimates to be calculated, they can be subject to potential biases and uncertainties ([@B59]). Such an indirect treatment comparison has to be regarded as a complementary assessment to clinical trials, because it cannot substitute direct evidence. However, in the absence of any head-to-head comparison, the indirect treatment comparison approach should be regarded as the most valuable way of estimating treatment effects in a statistically accurate manner ([@B60]). A systematic review and meta-analysis was conducted at an appropriate time with enough high quality data available for extraction by a comprehensive and robust search strategy. Also, the statistical power of this systematic review was limited by the small sample sizes of these studies, which ranged from 54 to 903 participants. It is well known that smaller studies are prone to publication bias and generate less reliable estimates of the size effect for any association. In [Supplementary Figures 2](#f10){ref-type="fig"}-[7](#f15){ref-type="fig"}, these funnel plots show an asymmetrical distribution of studies with low statistical power clearly. We applied a rigorous inclusion/exclusion criterion, different subgroups to identify studies, fully outcomes of interest (PFS, OS, ORR), bias adjusted data, strict criteria with Jadad scales to evaluate the quality of the included studies, and advanced network analysis of HR for PFS. Here, we provide up-to-date information of the network diagram of HR for PFS with regard to the current targeted therapies on mRCC which may worth reference on the clinical decision.
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In conclusion, our data suggest that targeted therapy with VEGF(r)-TKI & mTOR inhibitor is associated with superior efficacy for treating advanced RCC with improved PFS, OS and higher ORR compared to placebo and IFN-α. Agents targeting VEGF and mTOR pathways improve PFS in both first-line and second-line settings. In the light of this available evidence, there is no statistically significant PFS difference between BEV+IFN and TKIs in first-line mRCC therapy. Network diagram of pooled HR for PFS demonstrates axitinib and everolimus were more effective as the second line agents after failure of an initial VEGF(r)-TKI & mTOR treatment. In summary, here we give a comprehensive overview of current targeted therapies of advanced RCC and it may provide an evidence for the adequate targeted therapy selection. While acknowledging inherent bias in indirect treatment comparisons, upon consideration of each of the factors outlined in this review, the adequate treatment decision criteria of mRCC with targeted therapies remain considered with the safety and tolerability of agents and further robust large sample head-to-head RCTs are warranted to confirm our conclusion.
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**SUPPLEMENTARY PROTOCOL**

**Indirect treatment comparison (ITC) of everolimus vs. sorafenib for PFS**

**1. Overview of selected RCTs reported everolimus and sorafenib**

  Reference        Trial name    Intervention   Comparator   Patients   Outcomes           PFS       HR                 P
  ---------------- ------------- -------------- ------------ ---------- ------------------ --------- ------------------ ----------
  Ratain, 2006     NCT00079612   Sorafenib      Placebo      32/33      **PFS,** ORR       5.5/1.4   0.42 (0.20-0.91)   0.009
  Escudier, 2007   TARGET        Sorafenib      Placebo      451/452    OS, **PFS,** ORR   5.5/2.8   0.51 (0.43-0.60)   \<0.0001
  Motzer, 2008     RECORD-1      Everolimus     Placebo      272/138    OS, **PFS**, ORR   4.0/1.9   0.30 (0.22-0.40)   \<0.0001

**2. Pooled HR for PFS comparing sorafenib versus placebo via meta-analysis**

![](1677-5538-ibju-44-02-0219-gf16){#d35e5707}

**3. Indirect treatment comparison: efficacy connections between the pivotal trials**
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**4. Indirect comparison methodological procedures in detail**

           Description                                                  Formula                                       Everolimus         Sorafenib
  -------- ------------------------------------------------------------ --------------------------------------------- ------------------ ------------------
  Start    Basis data: HR for PFS vs PBO                                PFS HR (95% CI) vs PBO                        0.30 (0.22-0.40)   0.51 (0.43-0.59)
  Step 1   Calculation of the Ln (HR)                                   Ln (HR)                                       -1.20              -0.67
  Step 2   Calculation of the HR~ITC~                                   HR~ITC~ = EXP{Ln(HR)~Eve~-LN(HR)~Sor~}        0.59               
  Step 3   Calculation of the SE Ln (HR)                                SE~Ln(HR)~ = {Ln(UCI)-Ln(LCI)}/3.92           0.15               0.08
  Step 4   Calculation of the SE~ITC~                                   SE~ITC~ = SQRT(SE~Eve~ ^2^ + SE~Sor~ ^2^)     0.17               
  Step 5   Calculation of the 95% CI~ITC~                               95% CI~ITC~ = EXP{Ln(HR~ITC~)±1.96×SE~ITC~}   (0.42-0.82)        
  Result   ITC HR (Everolimus vs Sorfenib) = 0.59 (95% CI: 0.42-0.82)                                                                    

**Eve =** Everolimus; **Sor =** Sorafenib; **PBO =** Placebo; **ITC =** indirect treatment comparison; **PFS =** progression free survival; **HR =** hazard ratio; **95% CI =** 95% confidence interval; **SE =** standard error; **UCI =** upper CI; **LCI =** lower CI.

**5. Network diagram of a ranking of the three agents in order of superiority of HR**
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